REVIEW

Resolving the clinico-radiological paradox in multiple sclerosis [version 1; peer review: 3 approved]

Declan Chard ^{1,2}, S Anand Trip^{1,2}

¹National Institute for Health Research (NIHR) University College London Hospitals (UCLH), Biomedical Research Centre, London, UK

²NMR Research Unit, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK

V1 First published: 12 Oct 2017, 6(F1000 Faculty Rev):1828
<https://doi.org/10.12688/f1000research.11932.1>

Latest published: 12 Oct 2017, 6(F1000 Faculty Rev):1828
<https://doi.org/10.12688/f1000research.11932.1>

Abstract

Understanding the clinico-radiological paradox is important in the search for more sensitive and specific surrogates of relapses and disability progression (such that they can be used to inform treatment choices in individual people with multiple sclerosis) and to gain a better understanding of the pathophysiological basis of disability in multiple sclerosis (to identify and assess key therapeutic targets). In this brief review, we will consider themes and issues underlying the clinico-radiological paradox and recent advances in its resolution.

Keywords

multiple sclerosis, clinico-radiological paradox, MRI

Open Peer Review

Approval Status

	1	2	3
version 1 12 Oct 2017

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Hans Lassmann**, Medical University of Vienna, Vienna, Austria
2. **Maria Assunta Rocca**, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy
3. **Àlex Rovira**, Autonomous University of Barcelona, Barcelona, Spain

Any comments on the article can be found at the end of the article.

Corresponding author: Declan Chard (d.chard@ucl.ac.uk)

Author roles: **Chard D:** Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Trip SA:** Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: Declan Chard has received honoraria (paid to his employer) from Ismar Healthcare NV, Swiss MS Society, Excemed (previously Serono Symposia International Foundation), Merck, Bayer and Teva for faculty-led education work; Teva for advisory board work; meeting expenses from Merck, MS Trust, National MS Society, Novartis, Société des Neurosciences and Teva; and has previously held stock in GlaxoSmithKline. Anand Trip has received honoraria from Teva for faculty-led education work; Biogen, Novartis, Roche and Teva for advisory board work; Biogen, Novartis and Teva for educational meeting expenses.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Chard D and Trip SA. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Chard D and Trip SA. **Resolving the clinico-radiological paradox in multiple sclerosis [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):1828 <https://doi.org/10.12688/f1000research.11932.1>

First published: 12 Oct 2017, 6(F1000 Faculty Rev):1828 <https://doi.org/10.12688/f1000research.11932.1>

Introduction

The clinical course of multiple sclerosis (MS) is diverse and unpredictable: Some people develop rapidly evolving neurological deficits, whereas others accrue little or no detectable neurological deficit over decades¹. Magnetic resonance imaging (MRI) is now firmly established as a key tool in the diagnosis of MS², based on its ability to show white matter (WM) lesions with a typical spatial and temporal distribution for MS. However, the number and volume of WM lesions explain only a small fraction of the diversity of clinical outcomes in MS, and this mismatch has been termed the clinico-radiological paradox³.

This apparent paradox would matter less if we had clinical tools that were able to sensitively and reliably measure MS progression; however, scores such as the Expanded Disability Status Scale (EDSS) have well-recognised limitations⁴, one of which is relatively limited sensitivity to change in individuals. Some MRI measures are much more sensitive to change, but their clinical relevance is debated, in part due to the clinico-radiological paradox. Despite this, and because of greater sensitivity to change, MRI is now routinely used as the primary outcome in early phase treatment trials. While associations between the accrual of WM lesions and MS relapses are modest, it has been shown that a treatment effect seen on WM lesion accrual is a good predictor of the likely effects on relapses⁵.

The clinico-radiological paradox has also assumed a greater relevance with the advent of treatments that suppress relapses and, very recently, slow progression. Given the limited sensitivity of clinical measures for ongoing disease activity, there has been increasing interest in using composite clinical and MRI measure of disease activity and treatment efficacy (for example, 'no evidence of disease activity' assessments based on relapses, clinical progression and MRI measures of new lesion formation). However, in this regard, low levels of MRI-apparent disease activity may not (on their own) be associated with a substantial risk of further clinical events⁶.

Understanding the clinico-radiological paradox is important in the search for more sensitive and specific surrogates of relapses and disability progression (such that they can be used to inform treatment choices in individual people with MS) and to gain a better understanding of the pathophysiological basis of disability in MS (to identify and assess key therapeutic targets). In this brief review, we will consider themes and issues underlying the clinico-radiological paradox and recent advances in its resolution.

Pathological abnormalities in multiple sclerosis

The pathological effects of MS are multifaceted and variable, and the location, nature, extent and intensity of pathology are all relevant to clinical outcomes. While the most conspicuous abnormality is the presence of demyelinating lesions in WM, there is much more to the pathology of MS than WM lesions. Grey matter (GM) lesions are seen throughout the course of MS⁷ and, in people with long-standing progressive MS, may actually be more extensive than lesions in WM⁸. Extra-lesional tissues are also abnormal with, for example, glial abnormalities and reduced axonal densities seen in WM⁹ and glial abnormalities, and loss of dendrites

and neurons, in GM (for example, 10). Lesions themselves are heterogeneous, sufficiently so that WM subtypes have been defined¹¹, and within lesions there may be differing degrees of inflammation, demyelination and remyelination, and axonal loss, all of which may influence their functional consequences. Pathology in MS is also not spatially uniform. Demyelinating lesions tend to form around the lateral ventricles¹², and GM lesions occur most often in the cortical layers close to the surface of the brain⁸. Neurodegeneration also affects some regions more than others (for example, retrograde neurodegeneration may preferentially affect deep GM)¹³. Elements of MS pathology (for example, brain WM lesion loads) can vary substantially among people with MS, even when they have seemingly similar clinical outcomes.

Measurement characteristics

When we measure, we do so with varying degrees of overlying noise and underlying specificity, both of which can significantly reduce the apparent strength of associations between measures. When we repeat a measure, it is usual to observe variations in the results; whereas some of this variation may be due to a change in what is being measured, some will be due to measurement error; and with increasing measurement errors, apparent associations between measures can be attenuated (Figure 1). This can lead us to underestimate the clinical relevance of a pathological feature being assessed by using MRI. Similarly, the specificity of a measure can significantly affect associations: Few (if any) MRI or clinical measures reflect only one biological feature or its associated functional outcome, although some are more specific than others (see below).

Clinical measures

Clinical measures in MS seek to assess either the frequency of events over a given period (for example, relapse rate) or the level of neurological impairment at a given time. The most frequently assessed clinical measure of disease activity is the relapse rate. However, this has a number of limitations. It reflects new inflammatory lesions in clinically eloquent regions only, and lesions in other areas will go undetected. The estimation of a relapse rate is also open to recall bias (particularly where events are not recorded at the time of their occurrence), inter-observer variability (as each clinician may apply different clinical thresholds), and other factors such as silent infection, fatigue and low mood which can give rise to pseudo-relapses (that is, a transient worsening of symptoms that is not due to new inflammatory activity)¹⁴.

With regard to measures of neurological impairment, the EDSS¹⁵ is the most widely used measure of disability in MS. It produces a score based on symptoms and signs in eight functional systems, walking ability and activities of daily living. Scores are on an ordinal scale from 0 (asymptomatic with normal examination) to 10 (death due to MS). Scores of 0–3.5 reflect neurological impairment without a clear effect on mobility, 4–7.5 reflects impaired mobility, and 8–9.5 reflects effects on activities of daily living. Though easy to record and widely used, it has several limitations. For an ordinal scale measurement, parametric statistics should not be used without assessing whether the underlying assumptions of such statistics have been significantly breached, and non-parametric statistics are often preferred albeit with a potential loss of statistical power. It

Figure 1. Simulated perfectly correlated data, with a mean of 51 and a standard deviation (SD) of 15.1. Clockwise from the top left: No added noise, $r = 1$; noise SD = 5, $r = 0.89$; noise SD = 7.5, $r = 0.59$; and noise SD = 10, $r = 0.33$.

is also open to intra- and inter-variability when scoring, particularly with scores of less than 4¹⁶. Since its initial description, it has become apparent that other frequently occurring—and functionally significant—clinical manifestations of MS, such as cognitive impairment and fatigue, are relatively overlooked, and therefore it is not a true global measure of disability⁴.

To address some of the limitations of the EDSS, the Multiple Sclerosis Functional Composite (MSFC) was developed¹⁷. It assesses three important functional domains: ambulation (timed 25-foot walk), upper limb function (nine-hole peg test) and cognition (paced auditory serial addition task, or PASAT)¹⁷. The results from each component are converted to a z-score based on values from a reference population, thus producing continuous rather than ordinal data. The MSFC has good intra- and inter-rater reliability and, importantly, also more explicitly assesses cognition. However, there is debate about whether to use the MSFC score or its components separately. Combining domains provides a relative assessment of the clinical effects of MS; but, unlike the EDSS score, it does not provide an easily interpretable measure of disability; for example, an EDSS score of 3.5 means that mobility is not impaired, whereas an MSFC z-score of 3.5 does not do so. In addition, small but significant changes in any of the domains may be diluted and so overlooked. Given that each domain included in the MSFC may be influenced to a greater or lesser degree by different aspects of MS pathology (for example, cortical neurodegeneration may be more relevant to cognitive impairment than motor function, whereas demyelination or axonal loss may be more relevant to motor function than cognitive impairment), the use of more specific

clinical outcome measures is likely to be more informative when investigating pathophysiological mechanisms.

While the MSFC is more comprehensive in its assessment of disability than the EDSS, there is still scope for this to be improved on. The PASAT has some practical drawbacks such as a requirement for mathematical skills, a ceiling effect, and it is disliked by test subjects. Furthermore, it does not encompass all aspects of cognitive function. Other measures of cognitive dysfunction have been proposed. The Symbol Digit Modalities Test (SDMT) measures information-processing speed and is more easily administered, better tolerated, and more reliable than the PASAT¹⁸. Building on the SDMT, a brief international cognitive assessment for MS (BICAMS) has been proposed which includes the SDMT with the addition of the California Verbal Learning Test and the Brief Visuospatial Memory Test¹⁹. This attempts to assess other aspects of cognitive dysfunction. The MSFC also does not assess domains such as vision and bladder or bowel function, which can also have substantial effects on the lives of people with MS⁴.

While the EDSS is not an ideal measure of the neurological effects of MS, it remains the most popular disability score in clinical practice, and pragmatically (owing to service constraints) it would be difficult to incorporate a more extensive assessment in most healthcare settings. In clinical trials, while there may be more scope to use additional clinical outcome measures, for new treatments to be licensed these would have to be accepted by regulatory authorities as being valid markers of efficacy.

Magnetic resonance imaging measures

MRI measures can be broadly divided into those that assess macro-structure (for example, brain volumes), micro-structure (for example, magnetisation transfer imaging and diffusion tensor imaging, or DTI), metabolic features (such as proton spectroscopy and perfusion) and function (functional MRI, or fMRI)²⁰. Here, to illustrate points, we will consider these in outline only.

As with pathological studies, WM lesions in MS are the most conspicuous abnormality on conventional MRI scans. The majority of WM lesions seen on histopathological examination are also identified on MRI, and about 60% are seen on T2-weighted scans and 70% on T2 fluid-attenuated inversion recovery (FLAIR) scans²¹. Though more extensive, GM lesions are much more difficult to identify on these scans; less than 5% of cortical lesions are seen on T2-weighted scans, and 5% on T2-FLAIR; for deep GM, about 15% and 40% respectively are seen²¹. Double inversion recovery improves on this; about 10% of cortical and deep GM lesions are detected²², and phase-sensitive inversion recovery may increase this further²³. However, while subpial GM lesions are the most extensive type seen histopathologically, they are rarely identified using MRI at 3T. MRI at higher field strengths, such as 7T, appears to improve on this²⁴ but currently is not widely available in clinical practice or for research. Seewann and colleagues have shown (at 1.5T) that the GM lesions detected using MRI are the ‘tip of the pathological iceberg’, differing in size rather than other pathological characteristics from those that go undetected²⁵. Practically, when correlations of lesions measures with clinical outcomes are considered, it is likely—given lower sensitivity to GM compared with WM lesion—that the clinical relevance of GM lesions (in particular subpial lesions) will be underestimated when compared with WM lesions.

It is well recognised that lesions may be pathologically diverse but can appear similar on MRI scans. For example, without the use of a contrast agent, it is not possible to determine whether a lesion is actively inflamed and demyelinating, chronically demyelinated or remyelinating. However, not all lesions seen on a T2/proton density-weighted scan are seen on a T1-weighted image, and the subset of lesions seen on T1-weighted scans appear to represent those that have sustained greater axonal injuries²⁶. Despite this, correlations of T2-weighted and T1-weighted WM lesion loads with clinical outcomes are similar²⁷, suggesting that the difference in axonal loss between these lesions is either of limited clinical relevance or that other factors (such as measurement errors) mask any additional contribution axonal loss may make (beyond demyelination) to the association between lesion measures and clinical outcomes.

Brain volume loss, a marker of brain atrophy, which reflects neurodegeneration^{28,29}, is an MRI measure that is increasingly being used in clinical trials, particularly in progressive MS. However, the optimal way to measure brain volume or atrophy has yet to be determined, and a variety of approaches have been tried³⁰. Methods can be divided into those that measure tissue volumes on each MRI scan independently and those that compare scans to assess differences. At a whole brain level, methods that compare scans (for example, as implemented in Structural Imaging

Evaluation, using Normalization, of Atrophy, or SIENA) rather than assess each scan independently appear to be significantly more robust and sensitive to differences³¹. However, brain volume loss does not affect all brain tissues and regions equally; for example, there is evidence that it occurs more rapidly in GM than in WM³². As such, regional brain volume loss may be diluted in whole brain measures, and it has proven challenging to develop regional volume measures that can robustly compare scans.

So far, we have considered MRI measures of the quantity of a given tissue, but, as noted above, clinically relevant pathological abnormalities can affect the quality of tissues too. For example, in normal-appearing WM, magnetisation transfer ratio (MTR) and DTI measures both have been shown to correlate with disability measures³³. However, measures of intrinsic tissue characteristics are not pathologically specific. For example, MTR correlates not only with myelin density but also with axonal density (which itself is correlated with myelin density) and gliosis^{34,35}. In progressive MS, neurodegeneration is thought to be a (if not *the*) major process responsible for neurological deficits³⁶. While brain atrophy reflects neurodegeneration, loss of axons and neurons does not necessarily lead to an equivalent reduction in brain volumes: With an accurate measure of neuronal and axonal density, we would be able to better estimate the actual amount of neurodegeneration rather than a small fraction of it.

Most MRI measures used in MS research assess structure, but some investigate metabolic and (indirectly) neuronal function. Of these, fMRI has been most studied to date but highlights the challenges of trying to assess localised neural activity³⁷. Neuronal activity occurs at the level of single cells, but fMRI works at a much coarser scale (typically several cubic millimetres). fMRI also does not assess neuronal activity directly but instead via its effects on blood flow and oxygen extraction. Therefore, there is a delay between neuronal activity and what is measured by fMRI. Other factors (both physiological and pathological) can significantly affect blood flow and oxygen extraction and so can further decouple fMRI associations with underlying neuronal activity. There are two main forms of fMRI: task-based (with a subject performing a specific activity, such as finger tapping or counting) and resting-state (with a subject at rest). These provide different information; task-based fMRI probes specific networks (for example, motor), whereas resting-state offers a more global but less network-specific assessment of brain function³⁷. Interpretation of fMRI findings is challenging, as there may be decreased and, paradoxically, increased regional activity in MS³⁸. Increased activation may be adaptive (reducing the functional impact of MS pathology) or maladaptive (having no beneficial effect on function or perhaps even being associated with greater functional impairments)³⁹, but these cannot be readily distinguished in cross-sectional studies. To determine the dynamic relationship between fMRI measures and clinical outcomes, longitudinal studies are required to clarify this³⁹.

Linking pathology to clinical outcomes

So far, we have noted technical issues with, and the composite nature of, clinical and MRI measures that may attenuate correlations. We have also considered how MS disease effects are

not evenly distributed and that regional effects may be diluted in whole brain measures and so overlooked. However, we have yet to consider the way in which the central nervous system is organised and in particular how neurological functions rely on the integrity of neural networks. This has significant implications for the way in which we seek to connect MS pathology with clinical outcomes, as pathology within networks may be undervalued in whole brain measures (Figure 2). Recognising this, studies have looked for associations between regional pathology and clinical outcomes. For example, with motor outcomes, it has been shown that abnormalities in the cortico-spinal tract are more closely linked with function than are measures derived from elsewhere in the brain⁴⁰. Similarly, when compared with whole brain measures, temporal lobe atrophy has been more closely linked with memory impairments⁴¹, as has more specific hippocampal atrophy⁴². Another region of particular interest in MS is the thalamus, which may be affected directly and through its extensive connections with other brain regions⁴³. It has been suggested that, owing to its highly connected nature, the thalamus may act as a ‘barometer’ of MS pathology⁴³. Although we have focused on brain measures in this review, it is also clear that pathology anywhere in the central nervous system can affect clinical outcomes in MS and may do so in addition to abnormalities in the brain (for example, spinal cord atrophy⁴⁴).

Furthermore, connectomics studies have started to model the integrity of networks from MRI data (that is, the ability for neural networks to transfer and process information and so deliver a functional outcome)⁴⁵. Rather than treating a network as a region

and using MRI to measure pathological effects averaged across it, investigators assess elements of the network separately and treat them as components, each of which has a different contribution to functional outcomes. Graph theory⁴⁵ provides a mathematical framework with which to model overall network characteristics on the basis of brain regions and the connection between them. A variety of measures can be derived from a graph theory analysis, and it has yet to be determined which measure (or measures) best represents the effects that pathology has on function. Despite this uncertainty and complexity, such analyses have already shown some promise in MS. For example, correlations of EDSS with network efficiency (calculated using DTI measures from motor network tracts, Spearman $r = -0.52$) are noticeably greater than correlations of EDSS with conventional MRI measures (log T2 lesion load $r = 0.27$ or brain volumes $r = -0.30$)⁴⁶. Associations of network efficiency with EDSS appear to increase further when two measures of tissue microstructure (DTI and MTR) are combined ($r = -0.77$).

In addition to structural MRI measures in MS, graph theory has been applied to functional measures such as fMRI (for example, disruption of network integrity has been linked with cognitive impairment^{47,48}) and magnetoencephalography data (showing abnormalities when comparing people with MS and controls⁴⁹). Considering structural and functional assessments of the brain together can provide useful insights into the mechanisms underlying disability in MS (for example,³⁸), but combining structural and functional measures in a unified assessment of network performance has, to the best of our knowledge, not yet been achieved in MS.

Figure 2. Schematic of the brain (light blue), a brain network (dark blue and green) and lesions (red). From left to right: Whole brain lesion measures; a region of interest-based assessment of lesions within the network of interest; a network-based assessment of lesions. In the whole brain assessment (left), lesion C will have a negligible effect on network performance and so will dilute associations with the associated clinical outcome. In a region of interest-based assessment of the network (middle), the effects of lesions A, B and D are considered proportional to the volume of the network involved and so may relatively over- or under-value the effects that each lesion has on the associated clinical outcome. In the network-based assessment (right), lesions in each brain region (dark blue) or connecting tract (green) are considered separately, so allowing the effects on outcomes to be weighted according to their location within the network. For example, lesion B involves three tracts and so may have a greater effect on network performance than lesions A and D (each of which affects two tracts).

Conclusions

Recognition of the clinico-radiological paradox in MS has inspired considerable research and has led to a reconsideration of MRI and clinical measures and the link between them. Since this was first raised, there has been considerable progress on several fronts, to a degree that the mismatch between clinical and MRI measures is less an unexplained paradox (and so perhaps the term 'clinico-radiological paradox' is increasingly a misnomer) and more a potentially reconcilable challenge. From an MRI perspective, there is growing interest in regional and network-specific assessments of pathology and in developing more pathologically specific measures. From a clinical outcomes perspective, composite scores (such as EDSS) are being rethought, and measures of more specific functions developed. Linking MRI measures and clinical outcomes remains challenging, but insights from connectomics studies are helping to bridge the gap.

Competing interests

Declan Chard has received honoraria (paid to his employer) from Ismar Healthcare NV, Swiss MS Society, Excemed (previously

Serono Symposia International Foundation), Merck, Bayer and Teva for faculty-led education work; Teva for advisory board work; meeting expenses from Merck, MS Trust, National MS Society, Novartis, Société des Neurosciences and Teva; and has previously held stock in GlaxoSmithKline.

Anand Trip has received honoraria from Teva for faculty-led education work; Biogen, Novartis, Roche and Teva for advisory board work; Biogen, Novartis and Teva for educational meeting expenses.

Grant information

The authors declared that no grants were involved in supporting this work.

Acknowledgements

Declan Chard has received research support from the MS Society of Great Britain and Northern Ireland, and Declan Chard and Anand Trip from the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

References

- Hutchinson M: **Truly benign multiple sclerosis is rare: let's stop fooling ourselves--commentary.** *Mult Scler.* 2012; **18**(1): 15.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Polman CH, Reingold SC, Banwell B, *et al.*: **Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.** *Ann Neurol.* 2011; **69**(2): 292–302.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Barkhof F: **MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS).** *Mult Scler.* 1999; **5**(4): 283–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- van Munster CE, Uitdehaag BM: **Outcome Measures in Clinical Trials for Multiple Sclerosis.** *CNS Drugs.* 2017; **31**(3): 217–36.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Sormani MP, Bruzzi P: **MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials.** *Lancet Neurol.* 2013; **12**(7): 669–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Río J, Castilló J, Rovira A, *et al.*: **Measures in the first year of therapy predict the response to interferon beta in MS.** *Mult Scler.* 2009; **15**(7): 848–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lucchinetti CF, Popescu BF, Bunyan RF, *et al.*: **Inflammatory cortical demyelination in early multiple sclerosis.** *N Engl J Med.* 2011; **365**(23): 2188–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Bö L, Vedeler CA, Nyland HI, *et al.*: **Subpial demyelination in the cerebral cortex of multiple sclerosis patients.** *J Neuropathol Exp Neurol.* 2003; **62**(7): 723–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Lassmann H: **Pathology and disease mechanisms in different stages of multiple sclerosis.** *J Neurol Sci.* 2013; **333**(1–2): 1–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Magliozzi R, Howell OW, Reeves C, *et al.*: **A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis.** *Ann Neurol.* 2010; **68**(4): 477–93.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kuhlmann T, Ludwin S, Prat A, *et al.*: **An updated histological classification system for multiple sclerosis lesions.** *Acta Neuropathol.* 2017; **133**(1): 13–24.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Lee MA, Smith S, Palace J, *et al.*: **Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis?** *Brain.* 1999; **122**(Pt 7): 1261–70.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Haider L, Zrzavy T, Hametner S, *et al.*: **The topography of demyelination and neurodegeneration in the multiple sclerosis brain.** *Brain.* 2016; **139**(Pt 3): 807–15.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Tallantyre EC, Causon EG, Harding KE, *et al.*: **The aetiology of acute neurological decline in multiple sclerosis: experience from an open-access clinic.** *Mult Scler.* 2015; **21**(1): 67–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Kurtzke JF: **Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).** *Neurology.* 1983; **33**(11): 1444–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Goodkin DE, Cookfair D, Wende K, *et al.*: **Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS).** Multiple Sclerosis Collaborative Research Group. *Neurology.* 1992; **42**(4): 859–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Cutter GR, Baier ML, Rudick RA, *et al.*: **Development of a multiple sclerosis functional composite as a clinical trial outcome measure.** *Brain.* 1999; **122**(Pt 5): 871–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Benedict RH, Duquin JA, Jurgensen S, *et al.*: **Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire.** *Mult Scler.* 2008; **14**(7): 940–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Benedict RH, Amato MP, Boringa J, *et al.*: **Brief International Cognitive Assessment for MS (BICAMS): international standards for validation.** *BMC Neurol.* 2012; **12**: 55.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Brown JW, Chard DT: **The role of MRI in the evaluation of secondary progressive multiple sclerosis.** *Expert Rev Neurother.* 2016; **16**(2): 157–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Geurts JJ, Bö L, Pouwels PJ, *et al.*: **Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.** *AJNR Am J Neuroradiol.* 2005; **26**(3): 572–7.
[PubMed Abstract](#)
- Seewann A, Kooi EJ, Roosendaal SD, *et al.*: **Postmortem verification of MS cortical lesion detection with 3D DIR.** *Neurology.* 2012; **78**(5): 302–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sethi V, Yousry TA, Muhlert N, *et al.*: **Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.** *J Neurol Neurosurg Psychiatry.* 2012; **83**(9): 877–82.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Kilsdonk ID, de Graaf WL, Soriano AL, *et al.*: **Multicontrast MR imaging at 7T in**

- multiple sclerosis: highest lesion detection in cortical gray matter with 3D-FLAIR. *AJNR Am J Neuroradiol*. 2013; **34**(4): 791–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. **F** Seewann A, Vrenken H, Kooij EJ, *et al.*: **Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis.** *Mult Scler*. 2011; **17**(10): 1202–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 26. van Walderveen MA, Kamphorst W, Scheltens P, *et al.*: **Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis.** *Neurology*. 1998; **50**(5): 1282–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Grimaud J, Barker GJ, Wang L, *et al.*: **Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study.** *J Neurol*. 1999; **246**(10): 961–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. **F** Popescu V, Klaver R, Versteeg A, *et al.*: **Postmortem validation of MRI cortical volume measurements in MS.** *Hum Brain Mapp*. 2016; **37**(6): 2223–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 29. Wegner C, Esiri MM, Chance SA, *et al.*: **Neocortical neuronal, synaptic, and glial loss in multiple sclerosis.** *Neurology*. 2006; **67**(6): 960–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Sastre-Garriga J, Pareto D, Rovira A: **Brain Atrophy in Multiple Sclerosis: Clinical Relevance and Technical Aspects.** *Neuroimaging Clin N Am*. 2017; **27**(2): 289–300.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Altmann DR, Jaspers B, Barkhof F, *et al.*: **Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis.** *Neurology*. 2009; **72**(7): 595–601.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 32. **F** Fisher E, Lee JC, Nakamura K, *et al.*: **Gray matter atrophy in multiple sclerosis: a longitudinal study.** *Ann Neurol*. 2008; **64**(3): 255–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 33. Filippi M, Preziosa P, Rocca MA: **Microstructural MR Imaging Techniques in Multiple Sclerosis.** *Neuroimaging Clin N Am*. 2017; **27**(2): 313–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
 34. Schmierer K, Scaravilli F, Altmann DR, *et al.*: **Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain.** *Ann Neurol*. 2004; **56**(3): 407–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Schmierer K, Tozer DJ, Scaravilli F, *et al.*: **Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain.** *J Magn Reson Imaging*. 2007; **26**(1): 41–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Correale J, Gaitanari MI, Yssraelit MC, *et al.*: **Progressive multiple sclerosis: from pathogenic mechanisms to treatment.** *Brain*. 2017; **140**(3): 527–46.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Smitha KA, Akhil Raja K, Arun KM, *et al.*: **Resting state fMRI: A review on methods in resting state connectivity analysis and resting state networks.** *Neuroradiol J*. 2017; **30**(4): 305–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 38. Schoonheim MM, Hulst HE, Brandt RB, *et al.*: **Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis.** *Neurology*. 2015; **84**(8): 776–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. **F** Enzinger C, Pinter D, Rocca MA, *et al.*: **Longitudinal fMRI studies: Exploring brain plasticity and repair in MS.** *Mult Scler*. 2016; **22**(3): 269–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 40. Reich DS, Zuckowski KM, Gordon-Lipkin EM, *et al.*: **Corticospinal tract abnormalities are associated with weakness in multiple sclerosis.** *AJNR Am J Neuroradiol*. 2008; **29**(2): 333–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Benedict RH, Zivadinov R, Carone DA, *et al.*: **Regional lobar atrophy predicts memory impairment in multiple sclerosis.** *AJNR Am J Neuroradiol*. 2005; **26**(7): 1824–31.
[PubMed Abstract](#)
 42. Damjanovic D, Valsasina P, Rocca MA, *et al.*: **Hippocampal and Deep Gray Matter Nuclei Atrophy Is Relevant for Explaining Cognitive Impairment in MS: A Multicenter Study.** *AJNR Am J Neuroradiol*. 2017; **38**(1): 18–24.
[PubMed Abstract](#) | [Publisher Full Text](#)
 43. Kipp M, Wagenknecht N, Beyer C, *et al.*: **Thalamus pathology in multiple sclerosis: from biology to clinical application.** *Cell Mol Life Sci*. 2015; **72**(6): 1127–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Lukas C, Knol DL, Sombekke MH, *et al.*: **Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.** *J Neurol Neurosurg Psychiatr*. 2015; **86**(4): 410–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 45. Bullmore E, Sporns O: **Complex brain networks: graph theoretical analysis of structural and functional systems.** *Nat Rev Neurosci*. 2009; **10**(3): 186–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Pardini M, Yaldizli Ö, Sethi V, *et al.*: **Motor network efficiency and disability in multiple sclerosis.** *Neurology*. 2015; **85**(13): 1115–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Rocca MA, Valsasina P, Meani A, *et al.*: **Impaired functional integration in multiple sclerosis: a graph theory study.** *Brain Struct Funct*. 2016; **221**(1): 115–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Eijlers AJ, Meijer KA, Wassenaar TM, *et al.*: **Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.** *Neurology*. 2017; **88**(10): 952–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Tewarie P, Steenwijk MD, Tijms BM, *et al.*: **Disruption of structural and functional networks in long-standing multiple sclerosis.** *Hum Brain Mapp*. 2014; **35**(12): 5946–61.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Àlex Rovira**

Section of Neuroradiology, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona, Barcelona, Spain

Competing Interests: No competing interests were disclosed.

2. **Maria Assunta Rocca**

Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy

Competing Interests: No competing interests were disclosed.

3. **Hans Lassmann**

Center for Brain Research, Medical University of Vienna, Vienna, Austria

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research